P-gp

P-gp modulator 3 is a potent, competitive allosteric modulator of P-glycoprotein (P-gp). This compound enhances the effectiveness of therapeutic agents by inhibiting P-gp-mediated efflux, thus promoting improved intracellular accumulation of drugs. It is particularly useful in research applications focused on drug resistance mechanisms and the development of multi-drug resistance inhibitors.

Bromotetrandrine is a potent inhibitor of P-glycoprotein (P-gp), targeting multidrug resistance (MDR) in cancer cells. This compound demonstrates significant reversal activity against MDR both in vitro and in vivo, likely due to its ability to inhibit P-gp overexpression and enhance intracellular accumulation of anticancer agents. As a brominated derivative of tetrandrine, Bromotetrandrine is a valuable reagent for evaluating MDR modulation in tumor research.

P-gp inhibitor 4 is a selective modulator of P-glycoprotein, exhibiting an EC50 of 94 nM. This compound enhances the transport of therapeutic agents across the gastrointestinal barrier and can restore the efficacy of doxorubicin in multidrug-resistant cancer cells. It serves as a valuable tool for research into overcoming drug resistance and improving drug delivery mechanisms.

P-gp Inhibitor 26 is a potent inhibitor of P-glycoprotein (P-gp), a key player in multidrug resistance mechanisms. It effectively reverses P-gp-mediated drug resistance in K562/A02 cells, making it a valuable tool for investigating therapeutic strategies aimed at overcoming multidrug resistance in cancer cells. This compound is suitable for use in research applications focused on enhancing the efficacy of antitumor agents.

Phosphatidylinositol-1,2-dioctanoyl sodium acts as a potent inhibitor of P-glycoprotein (P-gp) transport. This compound demonstrates significant and reproducible inhibition of transmembrane P-gp transport, independent of cell line and substrate. Its involvement in signal transduction and cell motility makes it valuable for research into drug absorption and disposition, as well as studies on multidrug resistance in cancer therapy.

CJZ3 is a reversible inhibitor of P-glycoprotein (P-gp), which enhances the intracellular accumulation of the substrate drug Rh123. This compound is of particular interest in studies focused on improving drug permeability across the blood-brain barrier (BBB). CJZ3 has applications in research aimed at overcoming multidrug resistance and optimizing therapeutic efficacy for central nervous system-targeted therapies.

9,10-trans-Dehydroepothilone D is a potent P-glycoprotein inhibitor. It exhibits significant antiproliferative activity against paclitaxel-resistant cell lines that overexpress this transporter, making it a valuable tool in cancer research. Additionally, 9,10-trans-Dehydroepothilone D demonstrates tubulin polymerization activity, contributing to its potential use in elucidating mechanisms of drug resistance and improving therapeutic strategies. This compound serves as a promising candidate for further studies in cancer treatment paradigms.

Isotenulin acts as an inhibitor of P-glycoprotein (P-gp), enhancing the ATPase activity of P-gp and effectively combating multidrug resistance (MDR) in cancer cells. It demonstrates cytotoxic effects in both multidrug-resistant KB-vin cells and sensitive HeLaS3 cells. Additionally, Isotenulin shows a synergistic effect when used in conjunction with chemotherapeutic agents such as Paclitaxel, Vinblastine, and Doxorubicin, making it a valuable tool for research in cancer therapeutics.

XR9051 is a specific modulator of P-glycoprotein, targeting multidrug resistance (MDR). This compound enhances the efficacy of chemotherapeutic agents by inhibiting P-glycoprotein activity, thereby improving drug accumulation in resistant cancer cells. XR9051 is primarily utilized in cancer research to investigate strategies for overcoming drug resistance and enhancing therapeutic outcomes.

8-Prenylchrysin is a C8-prenylated flavonoid that serves as a potent inhibitor of P-glycoprotein (P-gp). This compound demonstrates significant biological activity by modulating drug efflux, which can enhance the efficacy of chemotherapeutic agents. 8-Prenylchrysin is primarily utilized in cancer research to investigate its potential in overcoming multidrug resistance in tumor cells.

Encequidar hydrochloride is a potent P-glycoprotein (P-gp) inhibitor that enhances the oral bioavailability of P-gp substrate drugs. It exhibits exceptional potency with an IC50 of 0.63 nM, making it one of the most effective MDR1 inhibitors available. Encequidar significantly impedes the transepithelial transport of paclitaxel in MDCK monolayer cells, with an IC50 of 35.4 nM. This compound is valuable for research focused on pharmacokinetics and drug delivery systems.

Ardeemin, a P-glycoprotein inhibitor, effectively binds to and inhibits P-glycoprotein, thereby preventing the efflux of anticancer agents from cells. This mechanism helps to reverse the multidrug resistance phenotype in tumor cells, enhancing their sensitivity to chemotherapy. Ardeemin has demonstrated potential applications in cancer research, specifically in improving the efficacy of treatments for mammary carcinoma xenografts.

Jatrophane 5 is a natural compound derived from Jatropha carcas L., targeting P-glycoprotein (P-gp). It exhibits potent inhibitory activity against P-gp, surpassing that of R(+)-verapamil and Tariquidar in colorectal multi-drug resistant DLD1-TxR cells. This compound is valuable for research into overcoming multidrug resistance in cancer treatment and enhancing drug efficacy in resistant cell types.

NSC73306 is a thiosemicarbazone that acts as a cell-penetrating cytotoxic agent. It demonstrates heightened toxicity in cells that express functional P-glycoprotein (P-gp) compared to non-expressing cells. This compound is primarily utilized in research focused on drug resistance mechanisms and potential therapeutic strategies against multidrug-resistant cancers.

VU6007477 is a selective M1 positive allosteric modulator (PAM) with an EC50 value of 230 nM, notable for its ability to penetrate the blood-brain barrier. This compound also acts as a human P-glycoprotein (P-gp) substrate and exhibits moderate permeability, providing advantages in central nervous system (CNS) research. As a pyranyl amide derivative, VU6007477 is a valuable tool for investigating cholinergic seizure activity and related neurological disorders.

MS-073 (CP162398) is a potent inhibitor of P-glycoprotein (P-gp), a key transporter involved in multidrug resistance. By competitively inhibiting the binding of chemotherapeutic agents to P-glycoprotein, MS-073 effectively reverses resistance in drug-resistant cancer cells. This compound is valuable for research into overcoming therapeutic challenges in oncology and drug delivery.

MCI826 is a P-glycoprotein (P-gp) agonist that enhances the efflux of various substrates across cell membranes. Its primary biological activity focuses on modulating drug transport and influencing cellular drug accumulation. This compound is valuable in research applications related to pharmacokinetics, multidrug resistance, and therapeutic strategies involving P-gp.

Atazanavir-d9 is a deuterated analog of Atazanavir, a highly selective HIV-1 protease inhibitor. This compound targets the HIV-1 protease enzyme, facilitating the treatment of HIV infections with its ability to inhibit viral replication. Additionally, Atazanavir acts as both a substrate and inhibitor of CYP3A4, as well as an inducer of P-glycoprotein (P-gp). Furthermore, Atazanavir possesses inhibitory activity against SARS-CoV 3CLpro, with an IC50 of 3.49 μM, making it relevant for research in antiviral therapies.

Danofloxacin mesylate is a fluoroquinolone antimicrobial agent that exerts its bactericidal activity primarily through the inhibition of bacterial DNA gyrase, a crucial enzyme for DNA replication. This compound displays a broad spectrum of effectiveness against various bacterial strains. Additionally, Danofloxacin mesylate is recognized as a substrate for ATP-dependent efflux transporters, including P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2), making it relevant for studies on drug resistance mechanisms in bacteria. This agent is primarily utilized in veterinary medicine and research on antibiotic efficacy and resistance.

Verapamil-d6 hydrochloride is a deuterated derivative of Verapamil, a selective calcium channel blocker. It exhibits potent inhibition of P-glycoprotein (P-gp) and CYP3A4, making it valuable in cardiovascular research, particularly for conditions such as hypertension, arrhythmias, and angina. This isotopically labeled compound aids in pharmacokinetic studies and offers insights into drug metabolism and transport mechanisms.